Global assessment of disease burden in adolescents and adults with alopecia areata, vitiligo, or hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, non-interventional study will collect real-world clinical data and patient-reported outcomes from adolescents and adults with physician-confirmed non-segmental vitiligo, moderate-to-severe alopecia areata, or moderate-to-severe hidradenitis suppurativa. Participants will complete questionnaires (with caregiver support allowed for adolescents) and undergo routine clinical assessments at participating sites. Individuals currently enrolled in interventional clinical trials are excluded, though participation in other non-interventional registries is permitted. Data will be pooled across enrolling centers to characterize regional and severity-related differences in disease burden.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)
* Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Exclusion Criteria:

* Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)
* Unable or unwilling to comply with study requirements and PRO collection

Where it's running

• Hospital Britanico de Buenos Aires /ID# 278940
  Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina Recruiting
• Buenos Aires Skin /ID# 277637
  Buenos Aires, Argentina Recruiting
• Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 277634
  Buenos Aires, Argentina Recruiting
• Hospital Italiano de Buenos Aires /ID# 277636
  Buenos Aires, Argentina Recruiting
• Instituto de Neumonología y Dermatología /ID# 277635
  Buenos Aires, Argentina Recruiting
• Dermatology Research Institute - Blackfoot Trail /ID# 276548
  Calgary, Alberta, Canada Recruiting

+66 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Beth Rycroft
• Email: beth.rycroft@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding the factors influencing chronic inflammatory skin diseases

  This study is trying to understand what causes different types of chronic skin conditions, like eczema and psoriasis, to behave differently in patients over time.

  Recruiting University Hospital Schleswig-Holstein · Kiel · NCT05928169

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• EB06 vs placebo for adults with non-segmental vitiligo

  This study tests whether EB06 given by IV can safely and effectively help adults with moderate to severe non-segmental vitiligo compared with placebo.

  Recruiting Phase 2 Edesa Biotech Inc. · Edmonton, Alberta and 4 other locations · NCT07889492

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.